240 related articles for article (PubMed ID: 38236069)
1. Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies.
Augustin RC; Cai WL; Luke JJ; Bao R
Clin Cancer Res; 2024 May; 30(9):1724-1732. PubMed ID: 38236069
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
3. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.
DiNatale RG; Hakimi AA; Chan TA
Hum Mol Genet; 2020 Oct; 29(R2):R214-R225. PubMed ID: 33029628
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
5. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
6. The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy.
Yoon SJ; Lee CB; Chae SU; Jo SJ; Bae SK
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203237
[TBL] [Abstract][Full Text] [Related]
7. Applications of Single-Cell Omics in Tumor Immunology.
Liu J; Qu S; Zhang T; Gao Y; Shi H; Song K; Chen W; Yin W
Front Immunol; 2021; 12():697412. PubMed ID: 34177965
[TBL] [Abstract][Full Text] [Related]
8. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
9. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
10. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
[TBL] [Abstract][Full Text] [Related]
11. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
[TBL] [Abstract][Full Text] [Related]
12. Tissue biomarkers of immune checkpoint inhibitor therapy.
Davoudi F; Moradi A; Sadeghirad H; Kulasinghe A
Immunol Cell Biol; 2024 Mar; 102(3):179-193. PubMed ID: 38228572
[TBL] [Abstract][Full Text] [Related]
13. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.
Gohil SH; Iorgulescu JB; Braun DA; Keskin DB; Livak KJ
Nat Rev Clin Oncol; 2021 Apr; 18(4):244-256. PubMed ID: 33277626
[TBL] [Abstract][Full Text] [Related]
14. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
[TBL] [Abstract][Full Text] [Related]
15. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
16. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
17. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
18. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
19. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Choucair K; Morand S; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
Cancer Gene Ther; 2020 Dec; 27(12):841-853. PubMed ID: 32341410
[TBL] [Abstract][Full Text] [Related]
20. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
